Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors

NCT02453620 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02453620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02453620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 12, 2016
Completion date
September 11, 2027
Enrollment
57 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, breast adenocarcinoma, invasive breast carcinoma, malignant solid neoplasm